About Us
Retina navigation – a game changer in preserving the eyesight of patients
What does “OD-OS” stand for?
OD-OS denotes the right eye (Oculus Dexter) and left eye (Oculus Sinister), as is commonly used in everyday documentation by eye doctors. Furthermore, OD-OS also stands for Ophthalmic Diagnostics – Ophthalmic Surgery. And it is this unique combination of the two aspects of standard care that points to the company’s goal: OD-OS is breaking new ground in integrating both the diagnosis and therapy in one solution utilizing Retina Navigation.
OD-OS GmbH develops, manufactures, and markets Navilas® – the first fully digital system for navigated retinal laser treatment. Protecting the eyesight of patients with retinal diseases is our mission. To achieve this, our international team collaborates closely with doctors and clinical professionals worldwide to further enhance the gentle laser treatment of the retina with our unique Navilas® navigated laser system and to make it available for new applications.
A Legacy in Ophthalmology
Founded in 2008, OD-OS is an offshoot of SensoMotoric Instruments GmbH (SMI). After three years of development in Retina Navigation, OD-OS was established with a strong capital base, aiming to revolutionize retina treatment.
Commitment to Quality
As an ISO 13485 certified company, OD-OS ensures compliance with international quality standards. The Quality Management System of OD-OS GmbH and the Navilas® Laser System 577s have been certified in accordance with the Medical Devices Regulation (EU) 2017/745 (EU MDR).
Innovative Solutions
OD-OS continues to advance retina treatment with Navilas. Projects like the LADOS-Project and OCT-Navigation-Project, funded by the Ministry of Economic Affairs of Brandenburg and the EU, enhance treatment precision.
Winfried Teiwes, Ph.D.
Founder and CEO of OD-OS GmbH, redefining retinal laser treatments with tracking and guidance
- Co-Founder in 2008 and CEO
- NAVILAS Co-inventor
Career Opportunities
We offer exciting career paths for individuals passionate about medical technology, innovation, and retina care. Explore our current job openings and become part of a team that is shaping the future of retinal treatments.
Investors
OD-OS is able to operate on the strength of a secure financial base established by a broad
platform of renowned venture capital investment companies.
SMI develops and distributes measurement instruments and applications focused on the human eye and brain in areas like ergonomics, market research, and man-machine interaction. The company’s expertise lies in high-speed image processing, camera development, system design, and application software.
Based in Munich, MIG Fonds is one of Germany's leading venture capital companies. Since 2005, MIG has launched multiple funds, investing in over 20 innovative companies across Germany and Austria. With a portfolio valued at over 500 million Euros, MIG funds are primarily directed at private investors.
BC Brandenburg Capital GmbH supports small and medium-sized enterprises in Brandenburg, managing six funds with a total of 150 million Euros. It is a subsidiary of InvestitionsBank des Landes Brandenburg (ILB), focused on fostering innovation and business growth.
Funded Projects
This project was funded by the European Union through the European Regional Development Fund (ERDF), supporting the development of advanced medical technologies in Europe.
This initiative was funded by the Ministry of Economic Affairs of Brandenburg, supporting innovative technologies for retina treatment within the Brandenburg region.
The Central Innovation Programme for small and medium-sized enterprises (SMEs) is a funding programme of the Federal Ministry for Economic Affairs and Climate Action that aims to foster the innovative capacity of SMEs.